Immunoassay for Earlier Diagnosis of Neonatal Sepsis to Enable Appropriate Interventions
|
By LabMedica International staff writers Posted on 20 Oct 2023 |
|
Neonatal sepsis is a bloodstream infection that occurs in the first four weeks of a baby's life, and it comes with significant risks for severe illness or death. Because it often starts with vague symptoms but can quickly escalate to multiple organ failure, early detection and timely treatment are crucial. Babies with this condition don't usually show clear symptoms, making early diagnosis challenging. Measuring levels of IL-6 (interleukin-6) has proven useful in diagnosing neonatal sepsis early. IL-6 levels rise quickly in response to infection, quicker than other indicators, making it an effective early alert for inflammation, infection, or sepsis. Timely diagnosis allows healthcare providers to take immediate and suitable action, improving the chances for a good outcome for the newborn.
Roche’s (Basel, Switzerland) Elecsys IL-6 immunoassay is the first IL-6 test to be certified for use in the diagnosis of neonatal sepsis in countries accepting the CE Mark. The vitro diagnostic test quantitatively measures IL-6 levels in human blood serum and plasma. It helps doctors by enabling quicker identification of severe inflammatory responses, thereby speeding up the diagnosis of neonatal sepsis.
Faster diagnosis allows medical professionals to take quicker and more effective steps to improve the baby's prospects. The Elecsys IL-6 immunoassay is especially practical as it takes just 18 minutes to complete and requires only a small blood sample. Designed as an electrochemiluminescence immunoassay (ECLIA), the Elecsys IL-6 test is intended for use with cobas e immunoassay analyzers.
“Sepsis is one of the leading causes of death in newborns and we need to do everything we can to prevent these deaths," said Matt Sause, CEO of Roche Diagnostics. "Receiving the first approval for IL-6 use with newborns, is a significant step forward in helping clinicians confidently diagnose neonatal sepsis earlier and save more lives.”
Related Links:
Roche
 Assay.jpg)
Latest Molecular Diagnostics News
- First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
- New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
- Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
- First-of-its-Kind Blood Test Detects Trauma-Related Diseases
- Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
- Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
Channels
Clinical Chemistry
view channel
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Hematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
